)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cohance Lifesciences
Cohance Lifesciences (COHANCE) investor relations material
Cohance Lifesciences Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary6 Nov, 2026
Executive summary
Q2FY27 revenue rose 12.9% QoQ to INR 4,766 Mn but fell 14.2% YoY; adjusted EBITDA margin improved to 9.6% from 2.2% in Q1.
H1FY27 revenue declined 18.6% YoY to INR 8,989 Mn and adjusted EBITDA fell to INR 551 Mn; H2 is expected to deliver YoY revenue and EBITDA growth.
The Suryapet facility received a closure order after a fatal accident; operational and financial impact remains under assessment.
Financial highlights
Q2FY27 adjusted EBITDA was INR 459 Mn at a 9.6% margin, versus INR 1,288 Mn and 23.2% a year earlier; adjusted PAT was INR 74 Mn versus INR 709 Mn.
Q2 reported net profit was ₹2.27 crore versus ₹66.39 crore a year earlier; H1 reported net loss was ₹42.92 crore versus profit of ₹112.79 crore.
H1FY27 adjusted EBITDA was INR 551 Mn at a 6.1% margin, versus INR 2,629 Mn at 23.8%; adjusted PAT was a loss of INR 355 Mn.
Q2 material margin was 70.8%, down 377 bps YoY; H1 gross margin was 71.1% versus 73.8%, reflecting mix and lower AgChem contribution.
Q2 revenue was ₹476.65 crore; standalone Q2 revenue was ₹416.69 crore with net profit of ₹13.27 crore.
Outlook and guidance
H2FY27 revenue and EBITDA are expected to grow YoY and exceed H1, supported by Small Molecule deliveries, API+ resilience, Sapala growth, utilisation and improved mix.
Small Molecule Q3/Q4 order visibility and reloads improved; first deliveries from new commercial programmes are expected in Q4 FY27 or Q1 FY28.
FY27 Specialty Chemicals revenue is expected to decline YoY, versus the prior broadly flat outlook; newer programmes will not offset near-term pressure.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cohance Lifesciences
- FY22 growth lifted margins; CDMO leads a measured FY23 outlook.COHANCE
Q4 21/22 - CDMO-led growth and a ₹600 crore modernization plan anchor the FY21 outlook.COHANCEQ4 20/21
- Strong FY20 growth funded an expansion push, tempered by COVID-19 and execution risks.COHANCEQ4 19/20
- Muted FY23 results and cautious FY24 guidance meet a new Advent-led strategic chapter.COHANCEQ4 22/23
- Destocking weighed on FY24 results, while pipeline growth and merger scale support recovery prospects.COHANCEQ4 23/24
- Q1 FY27 revenue fell 23.1% YoY, but H2 growth is expected as recovery and integration strengthen.COHANCEQ1 26/27
- FY26 saw revenue and EBITDA decline, but margins improved and growth is expected in FY27.COHANCEQ3 25/26
- Q2 FY25 revenue up 12% YoY, driven by Pharma CDMO and Sapala; outlook remains strong.COHANCEQ2 24/25
- Q3FY25 revenue up 40% YoY, driven by Pharma CDMO growth and strong margins.COHANCEQ3 24/25
Next Cohance Lifesciences earnings date
Q3 26/2711 Feb, 2027
Cohance Lifesciences
Next Cohance Lifesciences earnings date
Q3 26/2711 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Suven Pharmaceuticals Limited is a pharmaceutical company engaged in the development, manufacturing, and supply of active pharmaceutical ingredients (APIs) and intermediates. The company primarily focuses on contract development and manufacturing services (CDMO) for global pharmaceutical companies, supporting drug discovery and commercial production. Its operations include process research, custom synthesis, and scale-up of complex molecules for use in various therapeutic areas. Suven Pharmaceuticals Limited serves clients across regulated and emerging markets. The company is headquartered in Hyderabad, India, and its shares are listed on the NSE.